Skip to main navigation Skip to main content

Page translation not available

This page is not available in the language that has been selected and will appear in English.

Search

Contact us

07 3737 4500

PO Box 3787

South Brisbane QLD 4101

A/Prof Hien Le

MBBS, FRANZCR

  • Radiation Oncologist

Biography

A/Prof Hien Le brings a holistic, evidence-based approach to his practice. As a passionate advocate for cutting-edge cancer therapies and innovative radiation therapy technology, he is dedicated to delivering comprehensive and patient-centred care.

A/Prof Hien Le is an experienced radiation oncologist who consults at multiple Icon Cancer Centre locations across South Australia including Windsor Gardens, Adelaide (Kurralta Park) and Noarlunga. He provides treatment services at Windsor Gardens and Noarlunga.

In 2003, he completed his Bachelor of Medicine, Bachelor of Surgery (MBBS) at the University of Adelaide and undertook specialist radiation oncology training and a clinical fellowship at the Royal Adelaide Hospital (RAH). In 2011, A/Prof Le became a fellow of the Royal Australian and New Zealand College of Radiologists (RANZCR) and received the RANZCR Windeyer Fellowship award. He completed his Windeyer clinical oncology fellowship at Mount Vernon Cancer Centre in the United Kingdom, where he gained extensive experience in CyberKnife and MRI-guided brachytherapy techniques. A/Prof Le subsequently received the RANZCR College Thomas Baker award, travelling to Massachusetts General Hospital in the United States to further his knowledge and understanding of proton beam therapy.

A/Prof Le enjoys a mixture of clinical work, contributing to leading national and international publications and conferences, and attending regular multidisciplinary meetings with his medical community colleagues. He is a radiation oncology staff specialist at RAH and was the first in South Australia to treat a patient with stereotactic ablative body radiation therapy (SABR). A/Prof Le is the chair of the South Australian neuro-oncology multidisciplinary meeting and a supervisor for Masters and PhD students investigating the management and biology of cancers. His commitment to cancer research is reflected in his roles as Head of Research in the Department of Radiation Oncology at RAH and Adjunct Associate Professor at the University of South Australia. A/Prof Le also continues to play a key role in the Australian Bragg Centre for Proton Therapy and Research team’s proton-photon comparative planning services.

As an active member of the Trans Tasman Radiation Oncology Group (TROG) and several leading cancer trial groups, A/Prof Le is lead principal investigator of several open clinical trials across different cancer types. In 2020, he was appointed chair of the TROG Particle Therapy Special Interest Group. He has been awarded a number of research grants including the Australian Research Data Commons platform grant (2020) and Medical Research Future Fund grant for the MASTERPLAN clinical trial (2018).

A/Prof Le speaks fluent English and Vietnamese, and looks forward to caring for patients and their loved ones in their preferred language. His clinical experience covers a broad range of solid tumour malignancies, with a special interest in brain and spinal (CNS) cancer, head and neck cancer, liver cancer, lung cancer and pancreatic cancer.

Publications

  • Nichols AC, Theurer J, Prisman E, Read N, Berthelet E, Tran E, Fung K, de Almeida JR, Bayley A, Goldstein DP, Le H, Hier M. Randomized Trial of Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Long-Term Results of the ORATOR Trial. Journal of Clinical Oncology. 2022 Jan:JCO-21.

  • Oar A, Lee M, Le H, Wilson K, Aiken C, Chantrill L, Simes J, Nguyen N, Barbour A, Samra J, Sjoquist KM. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer. BMC cancer. 2021 Dec;21(1):1-1.

  • Siva S, Bressel M, Mai T, Le H, Vinod S, de Silva H, Macdonald S, Skala M, Hardcastle N, Rezo A, Pryor D. Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial. JAMA Oncology. 2021 Aug 29.

  • Ball, D., Mai, G. T., Vinod, S., Babington, S., Ruben, J., Kron, T., … & Le, H. (2019). Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. The Lancet Oncology, 20(4), 494-503.

  • Nichols A, Theurer J, Prisman E, Read N, Berthelet E, Tran E, Fung K, de Almeida J, Bayley A, Goldstein D, Hier M, Sultanem K, Richardson K, Mlynarek A, Krishnan S, Le H, Yoo, J, MacNeil D, Winquist E, Hammond A, Venkatesan V, Kuruvilla S, Warner A, Mitchell S, Chen J, Corsten M, Johnson-Obaseki S, Eapen L, Odell M, Parker C, Wehrli B, Kwan K, Palma D. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. The Lancet Oncology. 2019 Aug 12.

Research

Trials being conducted by this doctor

ASPIRE

The Australian Particle Therapy Clinical Quality Registry (ASPIRE) is a prospective, observational, longitudinal study of paediatric, adolescent, young adult and rare adult tumour patients from a select group of tumour streams treated with radiation therapy. Comparing the long term toxicities of photon and proton radiation therapy.The registry has set an initial accrual goal of 50 patients per year until the registry is collecting national data, then it is anticipated there will be 400 patients per year recruited with a total of 4,000 participants in 10 years.There are no clinical interventions required for participants enrolled onto the registry. All enrolled participants will receive treatment, and follow-up care as pre-determined by their treating clinician, in accordance with the standard of care at the treating institution. All treatment interventions that participants receive will be recorded on the registry database from the patient medical record, including (but not necessarily limited to) surgery, immunotherapy and/or chemotherapy (systemic therapy), as part of the initial treatment regimen and any subsequent therapy. Follow up of outcomes, including disease response, treatment toxicities and any disease progression and or survival will be recorded from the patient medical record as that information becomes available. The Data Manager at each treating site will update the participant’s status in the REDCap database yearly from the available medical record and may also contact the referring or treating clinician directly to obtain follow-up results as required.Participants will remain on the registry and will be followed until death, withdrawal of consent, or the registry is terminated.Data collected is part of routine follow up care provided by the participants treating institution and collected from the medical record. There is no anticipated participant input.

Locations Adelaide